



WBB Securities Acts as Co-manager to TetraLogic Pharmaceuticals on \$47MM Convertible Senior Notes Transaction

TetraLogic closes private offering with institutional investors

**For Immediate Release
June 24, 2014**

SAN DIEGO, CA – WBB Securities acted as co-manager on a convertible senior notes transaction for TetraLogic Pharmaceuticals, Inc., a clinical phase biopharmaceutical company focused on discovering and developing novel small molecule therapeutics for oncology and infectious disease. TetraLogic announced the pricing of the offering to institutional investors on June 17, 2014. Today the company announced the closing of the transaction, raising an aggregate of \$47 million before fees and expenses.

TetraLogic intends to use the proceeds for general corporate purposes including the continued development of its lead compounds and other related research and development.

About WBB Securities

WBB Securities is a leading investment management, investment banking, and equity research firm. Established in 2001 and headquartered in San Diego, California, WBB Securities is a registered independent broker dealer and investment advisor with proprietary trading desks that have market-making capabilities. WBB Securities has built a nationwide team of respected senior investment and research professionals with a network of branches throughout the US serving institutional and high net worth clients. The firm also maintains an investment banking and equity research practice focused exclusively in the life sciences niche. www.wbbsec.com

About TetraLogic

TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. TetraLogic has two clinical-stage product candidates in development: birinapant and SHAPE. Birinapant is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors. SHAPE is entering Phase 2 trials for early-stage Cutaneous T-Cell Lymphoma. www.tetraLogicpharma.com